<?xml version='1.0' encoding='utf-8'?>
<document id="14739663"><sentence text="Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol."><entity charOffset="78-91" id="DDI-PubMed.14739663.s1.e0" text="acenocoumarol" /></sentence><sentence text="E7070 is a novel sulfonamide anticancer agent that arrests cancer cells at the G1/S boundary of the cell cycle"><entity charOffset="17-28" id="DDI-PubMed.14739663.s2.e0" text="sulfonamide" /></sentence><sentence text=" Three patients receiving chronic therapy with the oral anticoagulant acenocoumarol experienced bleeding and/or a prolonged prothrombin time after treatment with E7070 at a dose of 700 mg/m2 given as a 1-h infusion"><entity charOffset="70-83" id="DDI-PubMed.14739663.s3.e0" text="acenocoumarol" /></sentence><sentence text=" In vitro studies have shown that E7070 has the potential to inhibit several cytochrome P450 (CYP)-enzymes, including CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4" /><sentence text=" The major enzyme involved in the metabolism of acenocoumarol in man is CYP2C9"><entity charOffset="48-61" id="DDI-PubMed.14739663.s5.e0" text="acenocoumarol" /></sentence><sentence text=" This study was performed to investigate the interaction between E7070 and acenocoumarol"><entity charOffset="75-88" id="DDI-PubMed.14739663.s6.e0" text="acenocoumarol" /></sentence><sentence text=" Blood samples were obtained from two patients receiving daily oral maintenance treatment with acenocoumarol both prior to and following treatment with E7070"><entity charOffset="95-108" id="DDI-PubMed.14739663.s7.e0" text="acenocoumarol" /></sentence><sentence text=" In addition, we incubated acenocoumarol enantiomers with pooled human microsomes with and without E7070 and measured the in vitro plasma protein binding of acenocoumarol after incubation with E7070"><entity charOffset="27-40" id="DDI-PubMed.14739663.s8.e0" text="acenocoumarol" /><entity charOffset="157-170" id="DDI-PubMed.14739663.s8.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.14739663.s8.e0" e2="DDI-PubMed.14739663.s8.e0" /><pair ddi="false" e1="DDI-PubMed.14739663.s8.e0" e2="DDI-PubMed.14739663.s8.e1" /></sentence><sentence text=" Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2"><entity charOffset="31-44" id="DDI-PubMed.14739663.s9.e0" text="acenocoumarol" /><entity charOffset="190-203" id="DDI-PubMed.14739663.s9.e1" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.14739663.s9.e0" e2="DDI-PubMed.14739663.s9.e0" /><pair ddi="false" e1="DDI-PubMed.14739663.s9.e0" e2="DDI-PubMed.14739663.s9.e1" /></sentence><sentence text="56 and 1" /><sentence text="58 h*micromol/L) compared to the systemic exposure in the absence of E7070 (1" /><sentence text="87 and 1" /><sentence text="23 h*micromol/l)"><entity charOffset="0-13" id="DDI-PubMed.14739663.s13.e0" text="23 h*micromol" /></sentence><sentence text=" The formation of acenocoumarol metabolites was retarded by E7070 at already low concentrations (2"><entity charOffset="18-31" id="DDI-PubMed.14739663.s14.e0" text="acenocoumarol" /></sentence><sentence text="1 microM)" /><sentence text=" The plasma protein binding of acenocoumarol was reduced at higher concentrations of E7070 (259 microM)"><entity charOffset="31-44" id="DDI-PubMed.14739663.s16.e0" text="acenocoumarol" /></sentence><sentence text=" These results indicate that E7070 may primarily interact with acenocoumarol by reducing its systemic clearance"><entity charOffset="63-76" id="DDI-PubMed.14739663.s17.e0" text="acenocoumarol" /></sentence><sentence text=" Displacement of acenocoumarol's plasma protein binding by E7070 may also occur but to a minor extent" /><sentence text=" In the absence of careful monitoring this drug-drug interaction may result in hypoprothrombinemia and a hemorrhagic tendency" /><sentence text="" /></document>